Physician profile
Robert J Winn
NPI 1629096821
$2,728.85
in general payments reported to CMS, 2019-2025
24 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.92 · 2020: $343 · 2021: $572 · 2022: $765 · 2023: $272 · 2024: $472 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $798.39 | 2020-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $596.84 | 2020-2025 | |
| Abbvie INC. | $247.87 | 2021-2025 | Mavyret |
| Otsuka America Pharmaceutical, INC. | $132.74 | 2021-2025 | Rexulti |
| Braeburn INC. | $131.29 | 2023-2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.30 | 2021-2025 | Xifaxan |
| Indivior INC. | $102.88 | 2020-2025 | Sublocade |
| Alkermes, INC. | $87.70 | 2022-2023 | Vivitrol |
| Merck Sharp & Dohme LLC | $85.15 | 2023-2025 | Pifeltro, Delstrigo, Lagevrio |
| Amgen INC. | $63.44 | 2023 | |
| Pear Therapeutics (US), INC. | $53.41 | 2021 | |
| Janssen Biotech, INC. | $44.76 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.55 | 2024-2025 | Caplyta |
| Arbor Pharmaceuticals, INC. | $30.46 | 2020-2021 | |
| Allergan, INC. | $29.97 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Tolmar, INC. | $28.47 | 2024-2025 | Jatenzo |
| Genentech USA, INC. | $24.54 | 2021-2022 | |
| Melinta Therapeutics, LLC | $19.99 | 2021 | |
| Bausch Health US, LLC | $18.87 | 2024 | Wellbutrin, Aplenzin |
| Hologic Sales and Service, LLC | $15.19 | 2024 | Aptima |
| Scilex Pharmaceuticals INC. | $14.92 | 2019 | |
| Almatica Pharma LLC | $14.36 | 2025 | Loreev Xr |
| Radius Health, INC. | $13.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Winn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.